Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
32.04
USD
-1.42%
-2.02%
-13.82%
Presentation Operator MessageOperator (Operator)Good day, ladies and gentlemen, and welcome to...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Mar. 12
Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing
Mar. 05
MT
Progyny Announces $100 Million Share Repurchase Program; Shares Rise
Feb. 29
MT
Progyny, Inc. announces an Equity Buyback for $100 million worth of its shares.
Feb. 29
CI
Progyny, Inc. authorizes a Buyback Plan.
Feb. 28
CI
Progyny Shares Slump After Q4 Results
Feb. 28
MT
KeyBanc Adjusts Price Target on Progyny to $43 From $45, Maintains Overweight Rating
Feb. 28
MT
North American Morning Briefing : Stock Futures Fall Ahead of Key Inflation Data
Feb. 28
DJ
Progyny Q4 Adjusted Earnings, Revenue Rise
Feb. 28
MT
Transcript : Progyny, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Feb. 27
Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024
Feb. 27
CI
Earnings Flash (PGNY) PROGYNY Reports Q4 EPS $0.32, vs. Street Est of $0.12
Feb. 27
MT
Earnings Flash (PGNY) PROGYNY Reports Q4 Revenue $269.9M, vs. Street Est of $274.1M
Feb. 27
MT
(PGNY) PROGYNY Forecasts Fiscal Year 2024 EPS $1.54 - $1.59
Feb. 27
MT
Progyny, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 27
CI
Progyny Insider Sold Shares Worth $769,928, According to a Recent SEC Filing
Feb. 08
MT
Progyny Chosen as Preferred Fertility Benefits Provider by Vistia Health
Jan. 17
MT
Vistia Health Selects Progyny, Inc. as Its Preferred Fertility and Family Building Benefits Provider
Jan. 17
CI
Progyny Names Chief Commercial Officer, Chief Technology Officer
Jan. 11
MT
Progyny Insider Sold Shares Worth $2,500,156, According to a Recent SEC Filing
Jan. 11
MT
Progyny, Inc. Announces Executive Appointments
Jan. 11
CI
Transcript : Progyny, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
Jan. 09
Progyny Insider Sold Shares Worth $605,106, According to a Recent SEC Filing
Jan. 05
MT
Progyny Insider Sold Shares Worth $914,745, According to a Recent SEC Filing
Jan. 05
MT
Progyny Insider Sold Shares Worth $5,898,285, According to a Recent SEC Filing
Dec. 29
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
More about the company
Last Close Price
32.04
USD
Average target price
46.9
USD
Spread / Average Target
+46.38%
Consensus
1st Jan change
Capi.
-13.82% 3.08B +13.93% 125B +18.37% 101B -0.28% 39.69B -33.18% 36.86B -5.28% 20.05B -39.49% 993M -28.58% 337M
Other Managed Healthcare
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1